Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity

Immunity against the pre-erythrocytic stages of malaria is the most promising, as it is strong and fully sterilizing. Yet, the underlying immune effectors against the human Plasmodium falciparum pre-erythrocytic stages remain surprisingly poorly known and have been little explored, which in turn prevents any rational vaccine progress. Evidence that has been gathered in vitro and in vivo, in higher primates and in humans, is reviewed here, emphasizing the significant role of IFN-γ, either as a critical immune mediator or at least as a valuable surrogate marker of protection. One may hope that these results will trigger investigations in volunteers immunized either by optimally irradiated or over-irradiated sporozoites, to quickly delineate better surrogates of protection, which are essential for the development of a successful malaria vaccine

Interferon-gamma, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity

Abstract Immunity against the pre-erythrocytic stages of malaria is the most promising, as it is strong and fully sterilizing. Yet, the underlying immune effectors against the human Plasmodium falciparum pre-erythrocytic stages remain surprisingly poorly known and have been little explored, which in turn prevents any rational vaccine progress. Evidence that has been gathered in vitro and in vivo, in higher primates and in humans, is reviewed here, emphasizing the significant role of IFN-γ, either as a critical immune mediator or at least as a valuable surrogate marker of protection. One may hope that these results will trigger investigations in volunteers immunized either by optimally irradiated or over-irradiated sporozoites, to quickly delineate better surrogates of protection, which are essential for the development of a successful malaria vaccine

Age-associated gut microbiota impair hippocampus-dependent memory in a vagus-dependent manner

International audienceAging is known to be associated with hippocampus-dependent memory decline, but the underlying causes of this age-related memory impairment remain highly debated. Here, we show that fecal microbiota transplantation (FMT) from aged, but not young, animal donors into young mice is sufficient to trigger profound hippocampal alterations, including astrogliosis, decreased adult neurogenesis, decreased novelty-induced neuronal activation, and impairment in hippocampus-dependent memory. Furthermore, similar alterations were reported when mice were subjected to an FMT from aged human donors. To decipher the mechanisms involved in mediating these microbiota-induced effects on brain function, we mapped the vagus nerve–related (VN-related) neuronal activity patterns and report that aged FMT animals showed a reduction in neuronal activity in the ascending-VN output brain structure, whether under basal condition or after VN stimulation. Targeted pharmacogenetic manipulation of VN-ascending neurons demonstrated that the decrease in vagal activity is detrimental to hippocampal functions. In contrast, increasing vagal ascending activity alleviated the adverse effects of aged mouse FMT on hippocampal functions and had a promnesic effect in aged mice. Thus, pharmacogenetic VN stimulation is a potential therapeutic strategy to lessen microbiota-dependent age-associated impairments in hippocampal functions

Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses.

BACKGROUND: The true interest of genetic immunisation might have been hastily underestimated based on overall immunogenicity data in humans and lack of parallelism with other, more classical immunisation methods. PRINCIPAL FINDINGS: Using malaria Liver Stage Antigen-3 (LSA-3), we report that genetic immunization induces in chimpanzees, the closest relative of humans, immune responses which are as scarce as those reported using other DNA vaccines in humans, but which nonetheless confer strong, sterile and reproducible protection. The pattern was consistent in 3/4 immunized apes against two high dose sporozoite challenges performed as late as 98 and 238 days post-immunization and by a heterologous strain. CONCLUSIONS: These results should, in our opinion, lead to a revisiting of the value of this unusual means of immunisation, using as a model a disease, malaria, in which virulent challenges of volunteers are ethically acceptable

Phase I trial of a P.vivax CS protein derived synthetic vaccinecandidate

IP 1106-05-063-97G. Corradin, J.A. Lopez, S. Herrera. -- En: Annals of TropicalMedicine yParasitology. -- Vol. 92, no. 5;(1998) ; p. 539-551. -- Plamodium vivax malaria vaccine development / Myriam Arevalo, Socrates Herrera. -- En:;circumsporozoite protein in individuals naturally exposedto malaria / Myriam Arevalo, Anais Zully Valencia,;Molecular Immunology. -- Vol. 38 (2001) ; p. 443-455. -- Variants of the plasmodium vivax circumsporozoite;protein (VK210 and VK247) in colombian isolates. -- En: MemoriasInst Oswaldo Cruz,Rio de Janeiro. -- Vol. 96,;no. 5 (jul 2001) ; p. 709-712. -- Identification of HLA-A2restricted CD8+T-limphosyte to plasmodium vivax;circumsporozoite protein by immunized Aotus monkeys / Myriam Arevalo, M.A.Roggero, J.M. Gonzalez, J. Vergara,;ARTICULO(S) EN REVISTA: Mapping and comparison of the B-cellepitopes recognized on the plasmodium vivax;Juana Vergara. -- En: Parasity immunology. -- Vol. 24, no.3 (mar 2002) ;p. 161-169